A221805 Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy - Mercy Medical Center

A221805 Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy

Posted on: March 9, 2021

This phase II / III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, numbness, and muscle weakness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy. Eligibility includes being at least 18 years old and additional requirements that can be discussed with a clinical trials coordinator upon request.

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center